US.MRNA · Moderna

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 12.227734178126576,
        "turnoverUsdM": 4292.710869189999,
        "liquidityPoints": 0.8,
        "volatilityPoints": 0.3
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.MRNA",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 104.9238,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 24.5,
      "take_profit_price": 175.4603,
      "target_multiplier": 1.9,
      "technical_strength": 1.7,
      "take_profit_percent": 26.3
    },
    "positionPoints": 1.1,
    "stopLossPoints": 0.6,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.7533333333333334,
    "stopLossPercent": 15,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 82.2,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 57.2,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 25
  },
  "market": {
    "ma20": 76.7305,
    "ma50": 69.3885,
    "close": 138.89,
    "prevClose": 145.13,
    "avgVolume20": 25312024,
    "volumeRatio": 1.22,
    "changePercent": -4.3
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 25,
    "details": {
      "ret_5d": 1.1546695625193917,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 25,
      "vcp_bonus": 0,
      "vol_ratio": 1.2868072911917736,
      "ret_points": 18,
      "vol_points": 4,
      "range_ratio": 1.2786196474032379,
      "volat_points": 2,
      "day_range_pct": 0.11152717978256184,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 82.2,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 50,
        "contribution": 2.5
      },
      {
        "raw": 17.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 86,
        "contribution": 17.2
      },
      {
        "raw": 6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 40,
        "contribution": 6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 5.5,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 55,
        "contribution": 5.5
      },
      {
        "raw": 21,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 70,
        "contribution": 21
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 57.2,
    "details": [
      "基本面分析總分: 2.5/5分",
      "資金流分析總分: 17.2/20分",
      "市場環境分析總分: 6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 5.5/10分",
      "技術信號分析總分: 21/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.5,
      "資金流": 17.2,
      "市場環境": 6,
      "情緒分析": 3,
      "技術信號": 21,
      "風險管理": 5.5
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0.75,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 4292.710869189999,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "優秀",
        "items": {
          "cmfPoints": 3.2,
          "mfiPoints": 4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.MRNA",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.13
            }
          },
          "trend": {
            "score": 1.7999999999999998,
            "details": {
              "qqq": {
                "ma20": 710.3985018500001,
                "ma50": 713.2256020399999,
                "name": "QQQ",
                "close": 706.32001,
                "points": 0.4
              },
              "spy": {
                "ma20": 763.5459993000001,
                "ma50": 752.2638036,
                "name": "SPY",
                "close": 763.46997,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 12.227734178126576,
          "atrPoints": 1,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 1.7999999999999998
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141302906,
                "url": "https://finnhub.io/api/news?id=ae24124488dfc0866911faedd21b212807a0636639fce52024ad8f6a1a687f04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc. (NASDAQ:MRNA) saw its share price more than double week-on-week to hit a new record high after reporting stellar results from the clinical trial of its melanoma therapy candidate in partnership with Merck. During the week, the stock climbed by as much as 179 percent to touch a record high of $176.66, before paring […]",
                "category": "company",
                "datetime": 1787469799,
                "headline": "Moderna (MRNA) Soars 179% as Melanoma Therapy Candidate Rewrites Growth Story"
              },
              {
                "id": 141278397,
                "url": "https://finnhub.io/api/news?id=38dd0d7e7c6eb6285ae70cc42b7302f86dda418041d32af3c76017a0115b343f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers",
                "category": "company",
                "datetime": 1787342040,
                "headline": "Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players"
              },
              {
                "id": 141278398,
                "url": "https://finnhub.io/api/news?id=627be7edc9f9bb24e26e8db1d3eb01a347be9c47be9302779448c5d5f59825cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you still buy the dip?",
                "category": "company",
                "datetime": 1787340255,
                "headline": "Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet."
              },
              {
                "id": 141273836,
                "url": "https://finnhub.io/api/news?id=54587dab906d987614824cfab5a6a06e39d1174079f537b68a0616ac939e493d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/New-York--Ny--Usa---11-05-2024-Wall-Stre.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Retail investors talked up 5 hot stocks during the week (Aug. 17 to Aug. 21) on X and Reddit's r/WallStreetBets: MRNA, WMT, MSTR, AVGO, SPCX",
                "category": "company",
                "datetime": 1787335233,
                "headline": "MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week"
              },
              {
                "id": 141278410,
                "url": "https://finnhub.io/api/news?id=11965b7623d404e18587fc0c0bbc876ea040961b86425f3109227d7743d0a687",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the options chain hints at why this whipsaw is far from over.",
                "category": "company",
                "datetime": 1787324767,
                "headline": "Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session"
              },
              {
                "id": 141264452,
                "url": "https://finnhub.io/api/news?id=8799c7b1be844f7bdd70b8d12c7c28fc8dcbbf1604870732897f7c765a3b0b8b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Gut-Microbiome-Linked-Colon-Cancer.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Pharma Bro Martin Shkreli admits shorting Moderna at $80 just weeks before a landmark cancer vaccine win sparked a 177% stock explosion.",
                "category": "company",
                "datetime": 1787215976,
                "headline": "Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’"
              },
              {
                "id": 141264457,
                "url": "https://finnhub.io/api/news?id=0f35252255458197d640a9a6e84e4d446dab53e84ac4b4f95fe5bd54531381f7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Paris--France---June-16--2023-Elon-Musk-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software problem.",
                "category": "company",
                "datetime": 1787213910,
                "headline": "Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)"
              },
              {
                "id": 141261727,
                "url": "https://finnhub.io/api/news?id=593eab7b6696fb79c76c1ab87310ffe191bf52224478eb4fdd74003a3801cac6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Two-Vials-Of-The-Moderna-Vaccine-With-A-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.",
                "category": "company",
                "datetime": 1787182165,
                "headline": "Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight"
              }
            ],
            "raw_source": [
              {
                "id": 141310582,
                "url": "https://finnhub.io/api/news?id=37c77b353f564166487672d942c21d5b0eced09b4ede4b83d36496c9b06c59c3",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1787598301,
                "headline": "Stay informed with the top movers within the S&P500 index on Monday."
              },
              {
                "id": 141310120,
                "url": "https://finnhub.io/api/news?id=b4e7862ecff49c01c686f4ff93eb405072c170ffc8e5c83fda06da0f37f4a012",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1787594700,
                "headline": "What's going on in today's session: S&P500 most active stocks"
              },
              {
                "id": 141309650,
                "url": "https://finnhub.io/api/news?id=6cc3cc0b0ac81d07cd282ed985700804b5a3849ecc19d8e6a7d4d1c7a1848a2b",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.",
                "category": "company",
                "datetime": 1787590800,
                "headline": "The trading volume of these stocks is deviating from the norm in today's session."
              },
              {
                "id": 141308774,
                "url": "https://finnhub.io/api/news?id=0fbb69c795f1bcd179b38c2d46070486d6fbc6e32d205e66f21d16810365802c",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1787582101,
                "headline": "Monday's session: gap up and gap down stock in the S&P500 index"
              },
              {
                "id": 141310307,
                "url": "https://finnhub.io/api/news?id=48b8fa88bd71ad9473b96e5509ddc70b6ba7cf91f9ae99697aa25dfc525580c6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/24/Tempus-AI.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.",
                "category": "company",
                "datetime": 1787580171,
                "headline": "What’s Going On With Tempus AI Stock on Monday?"
              },
              {
                "id": 141310292,
                "url": "https://finnhub.io/api/news?id=51e21f3e9e89a69ade69beb2705a25f5ef509f927e49a56f97601ab66eb255f0",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1787578524,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141310309,
                "url": "https://finnhub.io/api/news?id=500ff84143e098023aa003de16ff4328e912669d15deed8a52a8cb911b31ca79",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/24/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Shares of Moderna are trading lower Monday morning, taking a breather following a multi-day surge driven by clinical trial success.",
                "category": "company",
                "datetime": 1787565422,
                "headline": "Moderna Stock Slides Monday Following Historic Rally: What's Going On?"
              },
              {
                "id": 141302707,
                "url": "https://finnhub.io/api/news?id=351dfe7f68e2c28e4d40783769fb6f7a700d7362c99c21188d8c8b276c972f91",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Tempus AI's latest acquisition is looking like a great move.",
                "category": "company",
                "datetime": 1787488500,
                "headline": "Why Tempus AI Skyrocketed This Week"
              },
              {
                "id": 141302906,
                "url": "https://finnhub.io/api/news?id=ae24124488dfc0866911faedd21b212807a0636639fce52024ad8f6a1a687f04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc. (NASDAQ:MRNA) saw its share price more than double week-on-week to hit a new record high after reporting stellar results from the clinical trial of its melanoma therapy candidate in partnership with Merck. During the week, the stock climbed by as much as 179 percent to touch a record high of $176.66, before paring […]",
                "category": "company",
                "datetime": 1787469799,
                "headline": "Moderna (MRNA) Soars 179% as Melanoma Therapy Candidate Rewrites Growth Story"
              },
              {
                "id": 141302633,
                "url": "https://finnhub.io/api/news?id=710f3c3ca6e342bdec112e491629522821f6eb5c5c8bf1a9882b2cb278aa4676",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.",
                "category": "company",
                "datetime": 1787415000,
                "headline": "2 Biotech Stocks Shaping Up for Major Breakouts"
              },
              {
                "id": 141302612,
                "url": "https://finnhub.io/api/news?id=76547bac59c31a668d5e46df733d737aea57e6553f790608f61b8ad98abfced1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Stocks fell this week as Treasury bond buybacks, oil prices, and Walmart earnings weighed on markets, while Bitcoin rallied; MarketBeat analysts cover Moderna, NVIDIA, Meta, RTX, and more.",
                "category": "company",
                "datetime": 1787400000,
                "headline": "MarketBeat Week in Review – 08/17 - 08/21"
              },
              {
                "id": 141278399,
                "url": "https://finnhub.io/api/news?id=82086bc1efdaa2e00d5b62aee111cce8180f32a2ecd47272d983de05a06c52ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Check out the companies making headlines this week:",
                "category": "company",
                "datetime": 1787388819,
                "headline": "Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical"
              },
              {
                "id": 141294364,
                "url": "https://finnhub.io/api/news?id=9c7c4b6e7a4bd983931392cae935ba5ee7de9fcf2e7462339dc649abae2c0a2a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/22/Bulls-and-Bears-1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.",
                "category": "company",
                "datetime": 1787385673,
                "headline": "Benzinga Bulls and Bears: Ross, Moderna, Webull"
              },
              {
                "id": 141277722,
                "url": "https://finnhub.io/api/news?id=8ae02c1a8c55194b821cc37baed5fd386d50c7034cb1a8377b58c0ef6f854110",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "",
                "category": "company",
                "datetime": 1787382761,
                "headline": "What Moved Markets This Week"
              },
              {
                "id": 141278394,
                "url": "https://finnhub.io/api/news?id=682b10a24c0fe3439d30e49918a13068df09a090fa5d18e903888984f117b0a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.",
                "category": "company",
                "datetime": 1787361546,
                "headline": "ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’"
              },
              {
                "id": 141278219,
                "url": "https://finnhub.io/api/news?id=350fe7c8ba98e6524dd17860ad5c469797b726189c22f238eecd4e743634c106",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's 130% day ran on five conditions. We screened the market for stocks like Moderna and found three names, none a biotech.",
                "category": "company",
                "datetime": 1787354045,
                "headline": "3 American Stocks Showing the Same Setup That Sent Moderna Up 177%"
              },
              {
                "id": 141278395,
                "url": "https://finnhub.io/api/news?id=b65b0ac5786dd2b0dce71b5e3f2603194a23e2f203ea0237c5a61f9d1c7c1541",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes \"Moderna and Merck's Cancer Vaccine Is a Marvel.\"",
                "category": "company",
                "datetime": 1787353141,
                "headline": "Moderna, Merck Cancer Vax Gives Hope"
              },
              {
                "id": 141278401,
                "url": "https://finnhub.io/api/news?id=c0c318a6613f04793c35da84472cfac03ee0702d00d8d6e7de919298c14b9dbd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The stock has gained over 20% in the past five days, marking its best week since early July.",
                "category": "company",
                "datetime": 1787350771,
                "headline": "SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation"
              },
              {
                "id": 141273220,
                "url": "https://finnhub.io/api/news?id=8140b108801b2d518124ff23a413996f21d5e457e117de7876aca0b97880d25a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna shares rise to close out a week of wild swings. Crypto stocks also extend their recent rally.",
                "category": "company",
                "datetime": 1787347080,
                "headline": "Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141278402,
                "url": "https://finnhub.io/api/news?id=c007d7ae352542bcd167be2873b9aa69ef81d0951a36bac9af3d7ff47e073bfd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "It's been a good week for healthcare, with one stock's dramatic gains driving the sector higher.  Moderna stock saw its best weekly performance ever, rising over 140%.  The stock surged after the pharmaceutical giant announced promising results out of trials for its cancer vaccine.",
                "category": "company",
                "datetime": 1787342256,
                "headline": "Thank Moderna for the Healthcare Sector’s Standout Week"
              },
              {
                "id": 141278397,
                "url": "https://finnhub.io/api/news?id=38dd0d7e7c6eb6285ae70cc42b7302f86dda418041d32af3c76017a0115b343f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers",
                "category": "company",
                "datetime": 1787342040,
                "headline": "Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players"
              },
              {
                "id": 141278404,
                "url": "https://finnhub.io/api/news?id=788d907d139c172024a8da133d9395afb9596075f23fe3075ee239879373a942",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Investing.com -- A historic single-day move in biotech dominated the week, while a Treasury liquidity announcement impacted crypto and metals. Two well-known consumer names went in opposite directions on earnings.",
                "category": "company",
                "datetime": 1787340370,
                "headline": "Investing.com’s stocks of the week"
              },
              {
                "id": 141278398,
                "url": "https://finnhub.io/api/news?id=627be7edc9f9bb24e26e8db1d3eb01a347be9c47be9302779448c5d5f59825cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you still buy the dip?",
                "category": "company",
                "datetime": 1787340255,
                "headline": "Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet."
              },
              {
                "id": 141272165,
                "url": "https://finnhub.io/api/news?id=60f0df094fa5500e24b2d1e119b1523344538360e16ca95eb13e8cd7ffae6ba6",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.",
                "category": "company",
                "datetime": 1787339101,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 141281302,
                "url": "https://finnhub.io/api/news?id=6be02ab1951d7f5d67c8ff2a149e3e913541c81dd4fadeef9117066b76b98239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Yesterday’s unusual options activity revealed a massive 20,000-contract bull call spread on Pacific Gas & Electric (PCG). The low-risk, high-reward October trade risks $1.2 million for a potential $8.8 million payout, eyeing potential California wildfire reforms.",
                "category": "company",
                "datetime": 1787337002,
                "headline": "Unusual Options Activity Shows 1 Institutional Trader Is Making a Big Bet on PG&E Stock"
              },
              {
                "id": 141271515,
                "url": "https://finnhub.io/api/news?id=c44337b50efe0da34e7f47d53a781801f081fdbdc9b1b80bf495179c51b14ae9",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the most active stocks in the S&P500 index on Friday's session. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1787335501,
                "headline": "Which S&P500 stocks are the most active on Friday?"
              },
              {
                "id": 141273836,
                "url": "https://finnhub.io/api/news?id=54587dab906d987614824cfab5a6a06e39d1174079f537b68a0616ac939e493d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/New-York--Ny--Usa---11-05-2024-Wall-Stre.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Retail investors talked up 5 hot stocks during the week (Aug. 17 to Aug. 21) on X and Reddit's r/WallStreetBets: MRNA, WMT, MSTR, AVGO, SPCX",
                "category": "company",
                "datetime": 1787335233,
                "headline": "MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week"
              },
              {
                "id": 141271514,
                "url": "https://finnhub.io/api/news?id=b62b5a1624ff2850df9325358f0ff808fb927cb74bae610bd929dc9712420e38",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "These stocks are making the most noise in today's session. Stay tuned for the latest updates!",
                "category": "company",
                "datetime": 1787335200,
                "headline": "Friday's session: most active stocks"
              },
              {
                "id": 141271041,
                "url": "https://finnhub.io/api/news?id=9231dfaaa078db6b0e4386a813af19bafd76733ef919ab02892aacbfdb3f019c",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Friday. Stay informed about the market activity below.",
                "category": "company",
                "datetime": 1787331900,
                "headline": "Which S&P500 stocks have an unusual volume on Friday?"
              },
              {
                "id": 141270976,
                "url": "https://finnhub.io/api/news?id=708327aa4cf03c9d0967d12cb84df44a2e6c3be635420cd2ec7b4c4b54c811d9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1787330101,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 141274436,
                "url": "https://finnhub.io/api/news?id=284f8db205b3026a9f7fd1a7d5e062ee29303414d25d0d0a5189774496cd7747",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Us-Treasury-Secretary--Scott-Bessent-Wal.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna's biggest one-day rally ever, Bitcoin's best week since February 2023, and Walmart's 9% slide capped a volatile week driven by Bessent's bond rescue.",
                "category": "company",
                "datetime": 1787328101,
                "headline": "Bessent's Bond Band-Aid, Bitcoin's Best Week Since 2023: This Week on Wall Street"
              },
              {
                "id": 141281303,
                "url": "https://finnhub.io/api/news?id=e572ad963a107439a57827d0ebbc1fcc3b86c5b9d38cc612ce1d602c423f8172",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock could catch the eye of investors looking for the next big AI play, Revere Asset Management's Don Vandenbord says.",
                "category": "company",
                "datetime": 1787327370,
                "headline": "Moderna Stock Is Just The Start: Why AI-Focused Money Might Flow Into Biotech"
              },
              {
                "id": 141278409,
                "url": "https://finnhub.io/api/news?id=0693331366acda03bfcd5a167bea14df1950cd4e7abffeb35a05ea64ba6e2429",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The market rally flashed some bearish signals. Moderna skyrocketed on a cancer vaccine while gold and bitcoin jumped. Walmart dived.",
                "category": "company",
                "datetime": 1787326311,
                "headline": "Stock Market Rally Buckles; Moderna, Gold, Bitcoin Surge While Walmart Tumbles: Weekly Review"
              },
              {
                "id": 141278410,
                "url": "https://finnhub.io/api/news?id=11965b7623d404e18587fc0c0bbc876ea040961b86425f3109227d7743d0a687",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the options chain hints at why this whipsaw is far from over.",
                "category": "company",
                "datetime": 1787324767,
                "headline": "Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session"
              },
              {
                "id": 141278075,
                "url": "https://finnhub.io/api/news?id=ffe6cb0273861f20770610b9b0624ed6673a06dae9f7dc14902717e568c95c6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "JPMorgan layoffs hit highest since 2015, Amazon expands drone delivery, Chinese tech IPOs outshine U.S. rivals, and more news to start your day.",
                "category": "company",
                "datetime": 1787317800,
                "headline": "Bonds, Cryptos, Moderna Play Havoc With Markets. 2 Reasons for More Chaos."
              },
              {
                "id": 141273478,
                "url": "https://finnhub.io/api/news?id=efefe9bbbeab1654bc7f7bef800af2a084503a6408f913658e7b1ab0e71a833a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Moderna-Logo-With-Vials-And-Syringe.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna stock soars on recent Phase 3 trial results. A look back at the company's IPO and the stock's ups and downs since.",
                "category": "company",
                "datetime": 1787317764,
                "headline": "If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now"
              },
              {
                "id": 141278039,
                "url": "https://finnhub.io/api/news?id=e68f6a3a542ae07d07afd9a4c2837484ae1d71fbd4f4419f681e7005fbb1abf7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The  exchange-traded fund, home to some large pharma companies and many smaller biotechs, has risen over 6% this week.  The main catalyst was  Moderna  and  Merck  announcement of  successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence.  “The read-through [from Merck and Moderna] to the others is probably indicative of a broader tailwind of pharma taking some strong actions to improve their long-term growth profiles,” says Cantor Fitzgerald analyst Carter Gould.",
                "category": "company",
                "datetime": 1787317680,
                "headline": "Pharma Stocks Have Rallied. 2 Stocks to Avoid—and 2 to Buy."
              },
              {
                "id": 141271561,
                "url": "https://finnhub.io/api/news?id=389571a61c544b9ab404b5772ede85abe1dc3388aa5cab3e96ab9099759802b8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Bitcoin-Hits-Record-109-000-Ahead-Of-Tru.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Stocks steadied Friday as bond yields stabilized, Robinhood and Coinbase surged on CLARITY Act optimism, and gold hit a three-month high.",
                "category": "company",
                "datetime": 1787317412,
                "headline": "Bitcoin Jumps Above $77,000, Gold Hits 3-Month Highs: Stock Market Today"
              },
              {
                "id": 141278313,
                "url": "https://finnhub.io/api/news?id=6bcc8911359f6782aad16e9be6acf31e86bcbc3c25bde6ccd190e36849300d35",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Futures rose after the Nasdaq closed below its Aug. 4 low, a bearish market signal. Bitcoin momentum continues.",
                "category": "company",
                "datetime": 1787317053,
                "headline": "Dow Jones Futures Rise After Bearish Market Signal; Bitcoin Keeps Surging"
              },
              {
                "id": 141271592,
                "url": "https://finnhub.io/api/news?id=4ccb9bd36bb8a00713c20c640e27a331b45cc37108e9197b705e906827562b67",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Stock-And-Buyback-Write-On-Sticky-Notes-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.",
                "category": "company",
                "datetime": 1787315770,
                "headline": "Why Is Arbutus Biopharma Stock Gaining Friday?"
              },
              {
                "id": 141271055,
                "url": "https://finnhub.io/api/news?id=5f4598b0d6ba255f594f708ce90e97cacf249bf22caddb167020847d33773921",
                "image": "https://image.cnbcfm.com/api/v1/image/107245920-1684930328222-gettyimages-1492705069-wm3_0004_2mhohkdz.jpeg?v=1787329951&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are some of the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1787314912,
                "headline": "Stocks making the biggest moves midday: Moderna, Robinhood, BJ's Wholesale, Coinbase & more"
              },
              {
                "id": 141274440,
                "url": "https://finnhub.io/api/news?id=52c264b602d4566df3a5af9cb729881c04c336b7bef807263347ed2c3351629a",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "JP Morgan  analyst Jessica Fye   maintains Moderna (NASDAQ:MRNA) with a Underweight and raises the price target from $40 to $77.",
                "category": "company",
                "datetime": 1787314078,
                "headline": "JP Morgan Maintains Underweight on Moderna, Raises Price Target to $77"
              },
              {
                "id": 141271225,
                "url": "https://finnhub.io/api/news?id=d2fb3acec40eb143a8d943119da90d9092dbd8876d9dabab946f1654d13fbc8c",
                "image": "https://image.cnbcfm.com/api/v1/image/108352798-6ED4-LateMorning-082126.jpg?v=1787327747&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "CNBC brings you fast, accurate, and actionable business news and market updates.",
                "category": "company",
                "datetime": 1787313695,
                "headline": "The Late Morning Rundown: August 21, 2026"
              },
              {
                "id": 141270540,
                "url": "https://finnhub.io/api/news?id=116c11c87c38da79036c16efcd11562a853d9083eec117f66078dbf626d0cc71",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2229006239/image_2229006239.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "SCHD beat bearish macro trends as ABT, MRK & AMGN surged. Learn why dividend growth makes waiting costly—and what to do now.",
                "category": "company",
                "datetime": 1787311688,
                "headline": "SCHD: We Were Horribly Wrong"
              },
              {
                "id": 141274441,
                "url": "https://finnhub.io/api/news?id=75bb137aea44f47bfd17ffe54415ef6589f9d8609752bb4b94002ea857dfd2b0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Kyiv--Ukraine---December-01--2020-Modern.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna's Phase 3 cancer vaccine breakthrough could mark a turning point as the biotech company looks to move beyond its COVID-era identity.",
                "category": "company",
                "datetime": 1787309089,
                "headline": "COVID-19 Made Moderna Famous: Cancer Could Define Its Future"
              },
              {
                "id": 141270389,
                "url": "https://finnhub.io/api/news?id=56e29be6ca6e87d3fa59efd1ea850109ec37dead66406b6fb56e45c0e983fa3b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Display-Of-Stock-Market-Quotes.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Dow Jones index gained around 350 points on Friday. MARA Holdings Inc (NASDAQ: MARA) rose sharply, while Bitcoin (CRYPTO: BTC) also traded higher. Other stocks recording gains include Evolution Metals (NASDAQ: EMAT), TRON (NASDAQ: TRON), Bakkt (NYSE: BKKT), Rezolute (NASDAQ: RZLT), Gemini Space Station (NASDAQ: GEMI), Robinhood Markets (NASDAQ: HOOD), Strive (NASDAQ: ASST), Moderna (NASDAQ: MRNA), Coinbase Global (NASDAQ: COIN), Bitdeer Technologies (NASDAQ: BTDR), and Circle Internet Group (NYSE: CRCL).",
                "category": "company",
                "datetime": 1787307510,
                "headline": "MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On Friday"
              },
              {
                "id": 141268893,
                "url": "https://finnhub.io/api/news?id=6ce35ac37bb20f3f0877546c5a59b6279b06bd0bba9d04f6c33f383c18cea0c3",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_2026_08_21T105840_288_f7f25158ae.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "US stocks closed sharply lower on Thursday, August 20, 2026, as Walmart's downbeat outlook wiped nearly 10% off the shares, President Trump threatened Iran with the harshest sanctions package ever from Monday, and long-dated Treasury yields ticked higher again. John Deere's Q3 beat and a bitcoin surge past $70,000 offered the only real bright spots.",
                "category": "company",
                "datetime": 1787301595,
                "headline": "Walmart's Guide-Down Sinks the Dow as Trump Readies an \"Economic D-Day\" for Iran"
              },
              {
                "id": 141263200,
                "url": "https://finnhub.io/api/news?id=de80fd99b19d51b1c063dd5d4eb7830387e2c641e2ad3bda312e7bbd5d6af86f",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's have a look at what is happening on the US markets on Thursday. Below you can find the most active S&P500 stocks in today's session.",
                "category": "company",
                "datetime": 1787249101,
                "headline": "Looking for the most active stocks in the S&P500 index on Thursday?"
              },
              {
                "id": 141263199,
                "url": "https://finnhub.io/api/news?id=c9bf85700aaf607389079bd2ea55ee977d782ea9d2036f135b78b20d51a2dd46",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Thursday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!",
                "category": "company",
                "datetime": 1787248800,
                "headline": "Thursday's session: most active stocks"
              },
              {
                "id": 141262580,
                "url": "https://finnhub.io/api/news?id=7331752cc419ad64f9aa6e49025d689af93df70838588261a963b920c9235e73",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's have a look at the S&P500 stocks with an unusual volume in today's session.",
                "category": "company",
                "datetime": 1787245500,
                "headline": "Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below."
              },
              {
                "id": 141262493,
                "url": "https://finnhub.io/api/news?id=e35621ca09fce0d3e1edebbfb4c083ea6617d2a571f2e19e5d99d4ad8722292d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1787243701,
                "headline": "Thursday's session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 141271233,
                "url": "https://finnhub.io/api/news?id=c8ad4054f6b93dc494f91f0d17333b275d49576ee3e3d66126158647f3689e2a",
                "image": "https://image.cnbcfm.com/api/v1/image/108352412-17872578651787257862-47886674828-1080pnbcnews.jpg?v=1787257864&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "CNBC's Kristina Partsinevelos joins 'Closing Bell' to discuss the stocks she's watching.",
                "category": "company",
                "datetime": 1787243677,
                "headline": "Moderna shares pull back"
              },
              {
                "id": 141261787,
                "url": "https://finnhub.io/api/news?id=ef70edb58f9fe1b11a1770035da318102536f2c67402e358f9a9b937fd482e0a",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1787236501,
                "headline": "What's going on in today's session: S&P500 gap up and gap down stocks"
              },
              {
                "id": 141263370,
                "url": "https://finnhub.io/api/news?id=25d499e46aeb182c99566a316b221ca050055e16c61d83cc8d1dd14cfb670a63",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Buy XBI now: SPDR S&P Biotech ETF up 34% since March on M&A and trial catalysts.",
                "category": "company",
                "datetime": 1787235957,
                "headline": "XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)"
              },
              {
                "id": 141266096,
                "url": "https://finnhub.io/api/news?id=12671ac5e83779828cb0ce8fe50860cdd8b73b4b7f4a086d45b45f6ef60a66ba",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Goldman Sachs  analyst Salveen Richter   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $67 to $120.",
                "category": "company",
                "datetime": 1787234272,
                "headline": "Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $120"
              },
              {
                "id": 141263028,
                "url": "https://finnhub.io/api/news?id=a416f35b58578fb8808f2f0ce869185a8f7a63179d21aedf5e629b09dbf3483f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962515/image_1386962515.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Virtus Biotech ETF (BBP) gets a buy rating: equal-weight, quarterly rebalanced exposure to FDA-approved biotechs, deal activity & GLP-1 tailwinds.",
                "category": "company",
                "datetime": 1787234055,
                "headline": "BBP: The Biotech ETF That Filters For FDA-Approved Drugs"
              },
              {
                "id": 141264444,
                "url": "https://finnhub.io/api/news?id=2aadb4debe16219f9578212ef6073d8a48dd765776e660a254ec7af57c751400",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Benzinga-Quick-Spark.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna closed up 176.97% on first-ever Phase 3 win for an mRNA cancer vaccine, then gave back as much as a quarter of it the next day.",
                "category": "company",
                "datetime": 1787233734,
                "headline": "QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History"
              },
              {
                "id": 141263663,
                "url": "https://finnhub.io/api/news?id=b9ae4613669603267f6c067feff6ec8de6891cf3e48fff5457fb7f1907a8f1c0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/3D-Illustration-Depicting-Cancer-Cells-I.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.",
                "category": "company",
                "datetime": 1787231698,
                "headline": "Why Iovance Biotherapeutics Stock Hit 52-Week High"
              },
              {
                "id": 141263630,
                "url": "https://finnhub.io/api/news?id=64f0887169335f9343a469b7b2728f518e8c07b180ed492548037ab2cd1a62c2",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Gainers\n\nIndaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday's regular session. The company's market cap stands at $125.2 million. \nBioVie (NASDAQ:BIVI) stock rose 30.85%",
                "category": "company",
                "datetime": 1787231181,
                "headline": "12 Health Care Stocks Moving In Thursday's Intraday Session"
              },
              {
                "id": 141262651,
                "url": "https://finnhub.io/api/news?id=c9d78559897470f3052b28bb595ce9dd1d065a7a355911da0c46f7898b000346",
                "image": "https://image.cnbcfm.com/api/v1/image/108348727-1786564871180-gettyimages-2289554840-golba-dailylif260803_npNAH.jpeg?v=1786564923&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are some of the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1787231148,
                "headline": "Stocks making the biggest moves midday: Walmart, Deere, CrowdStrike, Moderna & more "
              },
              {
                "id": 141262763,
                "url": "https://finnhub.io/api/news?id=3f3a28f79218cb81b53764c2f6a3e497a8c47216dad56246efc6c5c12b4bd996",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Us-Treasury-Secretary--Scott-Bessent-Wal.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Long-end Treasury yields snapped back toward 20-month highs; Walmart posted its worst session in four years.",
                "category": "company",
                "datetime": 1787230977,
                "headline": "Bessent's Bond Rescue Fizzles, Walmart Craters 9%: Stock Market Today"
              },
              {
                "id": 141261177,
                "url": "https://finnhub.io/api/news?id=710c4f6ba1bc6547fe0bdb24de23d157524b5f38b704e2396156c75b4c0b5bc2",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.",
                "category": "company",
                "datetime": 1787229301,
                "headline": "These S&P500 stocks that are showing activity before the opening bell on Thursday."
              },
              {
                "id": 141263641,
                "url": "https://finnhub.io/api/news?id=5d1c3279b1b545b5059b047cc554eb412cfac84ee11ad4eb6127fe31e9b9d83b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Close-up-View-Of-An-Abstract-Molecular-S.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.",
                "category": "company",
                "datetime": 1787227385,
                "headline": "Biotech Is Booming, But These 2 Stocks Missed the Memo"
              },
              {
                "id": 141266102,
                "url": "https://finnhub.io/api/news?id=3def7c9ef242d275477eb9ffae4c5db7607841cd95abfe0c1e1d5d2018a499b8",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "UBS  analyst Michael Yee   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $50 to $150.",
                "category": "company",
                "datetime": 1787226902,
                "headline": "UBS Maintains Neutral on Moderna, Raises Price Target to $150"
              },
              {
                "id": 141264450,
                "url": "https://finnhub.io/api/news?id=81953aae4b3cce9c57f1f27ba6c6ee7d0fe9fd5f5db41ca84814fbaf25814bd8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Moderna-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "William Blair upgraded Moderna to Outperform, citing higher intismeran approval odds and a multibillion-dollar oncology sales opportunity.",
                "category": "company",
                "datetime": 1787223773,
                "headline": "Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst"
              },
              {
                "id": 141264452,
                "url": "https://finnhub.io/api/news?id=8799c7b1be844f7bdd70b8d12c7c28fc8dcbbf1604870732897f7c765a3b0b8b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Gut-Microbiome-Linked-Colon-Cancer.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Pharma Bro Martin Shkreli admits shorting Moderna at $80 just weeks before a landmark cancer vaccine win sparked a 177% stock explosion.",
                "category": "company",
                "datetime": 1787215976,
                "headline": "Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’"
              },
              {
                "id": 141261780,
                "url": "https://finnhub.io/api/news?id=bdf52e47b57a45524ab51963ebe64f43e347599af34cade8a165280971f79d8d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/New-York--Ny--Usa---11-05-2024-Wall-Stre.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Editor’s note: The ETFs data was updated and economic data was added\n\n\n\nU.S. stock futures were lower on Thursday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, following Wednesday’s higher",
                "category": "company",
                "datetime": 1787214974,
                "headline": "Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Fall as Trump Launches ‘Operation Economic Fury’ on Iran— BULL, WMT, MRK Stock in Focus (UPDATED)"
              },
              {
                "id": 141264455,
                "url": "https://finnhub.io/api/news?id=a927e529fa3d828492e6c559d766861b09c7978686f9c68f42c09ae836f8fede",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Tempus-AI.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Tempus AI (TEM) trades higher after positive Phase 3 mRNA cancer trial results spotlight its $1.5B acquisition of Personalis.",
                "category": "company",
                "datetime": 1787214954,
                "headline": "Why Is Tempus AI Stock Gaining Thursday?"
              },
              {
                "id": 141261710,
                "url": "https://finnhub.io/api/news?id=6eabbfd293f00b11fa7b0d65344a4f503d89c94b82d3fbd4985dd1bdd77570cb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Okta-Sign-Building-In-Soma-District--Okt.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.",
                "category": "company",
                "datetime": 1787213997,
                "headline": "Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday"
              },
              {
                "id": 141264457,
                "url": "https://finnhub.io/api/news?id=0f35252255458197d640a9a6e84e4d446dab53e84ac4b4f95fe5bd54531381f7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Paris--France---June-16--2023-Elon-Musk-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software problem.",
                "category": "company",
                "datetime": 1787213910,
                "headline": "Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)"
              },
              {
                "id": 141261740,
                "url": "https://finnhub.io/api/news?id=311bb1749a844fe1f48ea7e3177fe36789b5dfb762695268ea4d17fe4491b874",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Stuttgart--Germany---10-03-2022-Mobile-P.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losses in Q4 and exit of Gucci Beauty license.",
                "category": "company",
                "datetime": 1787213166,
                "headline": "Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session"
              },
              {
                "id": 141261028,
                "url": "https://finnhub.io/api/news?id=5b54ec56dfde684c05d3723c87da63c116166a04b8bff3d3ea948663950358c1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2280454849/image_2280454849.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. Learn more about TEM stock here.",
                "category": "company",
                "datetime": 1787212800,
                "headline": "Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance"
              },
              {
                "id": 141262655,
                "url": "https://finnhub.io/api/news?id=12541c546ed91799b5a30de416e367d481d0f6cba487ecf8383ccdcf6f3088f0",
                "image": "https://image.cnbcfm.com/api/v1/image/108342132-1785365195259-gettyimages-2280722565-TSCHNEIDER_68007_Coinbase_P8642202.jpeg?v=1785365264&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are the stocks posting the largest moves in the premarket.",
                "category": "company",
                "datetime": 1787211579,
                "headline": "Stocks making the biggest moves premarket: Walmart, Coinbase, Moderna, Alibaba & more"
              },
              {
                "id": 141262879,
                "url": "https://finnhub.io/api/news?id=4618f4d11e36cbd6fa11dd3e63cc0d74e1591588c4985e61d1664318a2073e61",
                "image": "https://image.cnbcfm.com/api/v1/image/108352044-17872247061787224703-47878999176-1080pnbcnews.jpg?v=1787224705&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Myles Minter, William Blair research analyst, joins 'Squawk Box' to discuss reports that an experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, what the breakthrough could mean for the companies and biotech industry going forward, and more.",
                "category": "company",
                "datetime": 1787211102,
                "headline": "Moderna, Merck cancer vaccine: William Blair's Myles Minter on what the breakthrough could mean"
              },
              {
                "id": 141260840,
                "url": "https://finnhub.io/api/news?id=165a75973e927f5ee7ac0860bb27345b6c37d6d881bd329434f668c0f8cd6f45",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2150626840/image_2150626840.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna and Merck have been running a large Phase III trial in over a thousand high-risk patients who had already had surgery to remove cutaneous melanoma tumors. Read more here...",
                "category": "company",
                "datetime": 1787210100,
                "headline": "Merck And Moderna's Melanoma Results"
              },
              {
                "id": 141260096,
                "url": "https://finnhub.io/api/news?id=508d178665ed408c01403249081d5127f914ba13062aa866c375984e312e5d86",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_2026_08_20T091541_987_28e8b314a3.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "US stocks eked out a modest gain on Wednesday, August 19, 2026, as Moderna nearly tripled on a landmark cancer vaccine readout, Marvell locked in a multi-billion Google chip deal, and Treasury doubled its long-bond buyback program. Fed minutes leaned more hawkish than expected.",
                "category": "company",
                "datetime": 1787209874,
                "headline": "Moderna Doubles on Melanoma Vaccine Win, Treasury Steps In to Cap Long-End Yields"
              },
              {
                "id": 141260788,
                "url": "https://finnhub.io/api/news?id=0fdd570409b9dec915804346a3cc51c0a36a85be17abe6e9713303e5262a3774",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165724876/image_2165724876.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna posts the biggest one-day S&P 500 gain this century. Bitcoin’s rally triggered a record short squeeze. The next AirPods could see the world around you.",
                "category": "company",
                "datetime": 1787209323,
                "headline": "Wall Street Breakfast Podcast: Moderna's $44B Booster"
              },
              {
                "id": 141266110,
                "url": "https://finnhub.io/api/news?id=83f2590d6953f33783d0083a2c45f3459090ee20828e906a4a02e4030d040493",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from $39 to $89.",
                "category": "company",
                "datetime": 1787207107,
                "headline": "Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $89"
              },
              {
                "id": 141261726,
                "url": "https://finnhub.io/api/news?id=1df584cc6d7462b6d1e0b4f407b260328535dd377744c94401139924e9f92628",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Financial-Market-Bubble-Concept-And-Over.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.",
                "category": "company",
                "datetime": 1787205550,
                "headline": "Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why"
              },
              {
                "id": 141261735,
                "url": "https://finnhub.io/api/news?id=97183838d09288bb46b91e9b040d0ef10114a6e0e3f7b22e6e63d66d94352db6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/WebullNew-York--Usa---April-25--2025-Web.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q2 results. Revenue of $198.83M beat estimates, while adjusted EPS of $0.05 also beat.",
                "category": "company",
                "datetime": 1787201621,
                "headline": "Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket"
              },
              {
                "id": 141264404,
                "url": "https://finnhub.io/api/news?id=1d1979a9f467d39bef8d2754efc67330a0bc4a6dbdc4bdf27cd1640729784c42",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Fear-and-Greed.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "U.S. stocks rise, Dow up 100+ points as Treasury's bond buyback decision eases yields. Mortgage apps fall, Lowe's reports mixed results, Moderna skyrockets on positive trial news.",
                "category": "company",
                "datetime": 1787197784,
                "headline": "Dow Gains Over 100 Points: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone"
              },
              {
                "id": 141262665,
                "url": "https://finnhub.io/api/news?id=b0b45e0aa2252c3139c04f29290c2ff67281f3d367193842f501696a5d7d533d",
                "image": "https://image.cnbcfm.com/api/v1/image/108347527-1786391307504-gettyimages-2277156932-WARSH_SWEAR_IN.jpeg?v=1786391350&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "President Donald Trump is raging against rates, vowing economic warfare on Iran and lending support to crypto regulation in a busy environment for investors.",
                "category": "company",
                "datetime": 1787192542,
                "headline": "CNBC Daily Open: Trump bemoans 'ridiculous rates'"
              },
              {
                "id": 141261727,
                "url": "https://finnhub.io/api/news?id=593eab7b6696fb79c76c1ab87310ffe191bf52224478eb4fdd74003a3801cac6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Two-Vials-Of-The-Moderna-Vaccine-With-A-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.",
                "category": "company",
                "datetime": 1787182165,
                "headline": "Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight"
              },
              {
                "id": 141262788,
                "url": "https://finnhub.io/api/news?id=623e3eca786973c739559db7e1fc03a28af1d6ca7ffa38063895e0af2ab9be22",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Displaying-Scrolling-Stock-Tickers-And-C.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Major U.S. indices closed higher on Wednesday, with the Dow Jones Industrial Average rising 0.22% to 53,463.05.",
                "category": "company",
                "datetime": 1787175285,
                "headline": "Moderna, Webull, Bitmine Immersion, Strategy and Merck: Why These 5 Stocks Are on Investors' Radars Today"
              },
              {
                "id": 141262666,
                "url": "https://finnhub.io/api/news?id=cc88f161424452008ad368e9f90f6cd385bdc432524e1179d0c4219cb7a6795f",
                "image": "https://image.cnbcfm.com/api/v1/image/108351875-1787178100146-gettyimages-2290607138-AFP_C62Z247.jpeg?v=1787178332&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "On Wednesday, the Treasury Department's decision to double its purchases of longer-dated bonds sent yields lower and gave stocks some breathing room.",
                "category": "company",
                "datetime": 1787175088,
                "headline": "CNBC Daily Open: Treasury attempts to rein in bond yields as U.S. debt swells past $40 trillion"
              },
              {
                "id": 141256542,
                "url": "https://finnhub.io/api/news?id=dcf9292a02ca751514a1e7e821a763badbc5d5265370944022394cfebadcb191",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.",
                "category": "company",
                "datetime": 1787173200,
                "headline": "What's going on in today's after hours session"
              },
              {
                "id": 141255652,
                "url": "https://finnhub.io/api/news?id=0b2b974f74465e36d03a0ffaa6c9f5f00e1e4069e49fb97916c4a492583c2ded",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.",
                "category": "company",
                "datetime": 1787166000,
                "headline": "Here are the top movers in Wednesday's session."
              },
              {
                "id": 141254986,
                "url": "https://finnhub.io/api/news?id=709907e313da67eb9297d61718e239cfbac798b8fcaa3222f3077e4bb4eb234f",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Get a pulse on the US markets on Wednesday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.",
                "category": "company",
                "datetime": 1787162400,
                "headline": "Which stocks are most active on Wednesday?"
              },
              {
                "id": 141262667,
                "url": "https://finnhub.io/api/news?id=2643f39d47ae10903f710f0ae88830c6b8673d1b1f0ef7651e6e5a3bd0d5993e",
                "image": "https://image.cnbcfm.com/api/v1/image/108351867-17871760881787176084-47868097620-1080pnbcnews.jpg?v=1787176087&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to talk Merck and Moderna's stock moves on new cancer data.",
                "category": "company",
                "datetime": 1787161915,
                "headline": "Mizuho's Jared Holz on Moderna's leg up on new cancer shot data"
              },
              {
                "id": 141262668,
                "url": "https://finnhub.io/api/news?id=5e728bc0b4fb4997d053d54879c5401e3b48ce55ceb4ace7a9d20f79018c0c5f",
                "image": "https://image.cnbcfm.com/api/v1/image/108351855-17871738141787173761-47867557643-1080pnbcnews.jpg?v=1787173813&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Courtney Breen, Bernstein, joins 'Closing Bell Overtime' to talk Merck and Moderna stocks rallying on news of cancer drug trial.",
                "category": "company",
                "datetime": 1787160044,
                "headline": "Bernstein's Courtney Breen talks the massive rally in Moderna stock"
              },
              {
                "id": 141254498,
                "url": "https://finnhub.io/api/news?id=a14e9232a459dfb79110228cde8185ff998722229b244931ed0f700428b0617d",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.",
                "category": "company",
                "datetime": 1787159100,
                "headline": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session."
              },
              {
                "id": 141254409,
                "url": "https://finnhub.io/api/news?id=9d113a09f48670d436e6f2252bf1887b5a026dfadda5e1b78c4e9f01efe715bf",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Wednesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1787157301,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 141254408,
                "url": "https://finnhub.io/api/news?id=198e074b54e3d960db761695aa9b068a0a667265e4bfdc92ccd4bfd2823ccac4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.",
                "category": "company",
                "datetime": 1787157000,
                "headline": "What's going on in today's session"
              },
              {
                "id": 141264463,
                "url": "https://finnhub.io/api/news?id=7bbf84c238e3a13000db20b9a045f91156c545d34a7eb025c6ef8670f5d06ace",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Moderna-Sign-With-Bold-Red-3D-Lettering-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Shareholders of Moderna stock saw big gains on Wednesday. The stock is part of President Donald Trump's portfolio.",
                "category": "company",
                "datetime": 1787156014,
                "headline": "Trump Adds to Wealth With Moderna Stock Gains: Here’s How Much President Made"
              },
              {
                "id": 141266117,
                "url": "https://finnhub.io/api/news?id=caaee8ac2547c40893332784816db2bb96e68ff2b76b0cb354e559f7db5448bf",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "William Blair  analyst Myles Minter   upgrades Moderna (NASDAQ:MRNA) from Market Perform to Outperform.",
                "category": "company",
                "datetime": 1787153749,
                "headline": "William Blair Upgrades Moderna to Outperform"
              },
              {
                "id": 141253496,
                "url": "https://finnhub.io/api/news?id=865016aa954b32bc2aa1313ff88956f0cf017e3f938aece960261cd4ce456bf8",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.",
                "category": "company",
                "datetime": 1787150102,
                "headline": "Which S&P500 stocks are gapping on Wednesday?"
              },
              {
                "id": 141255461,
                "url": "https://finnhub.io/api/news?id=8a923a2aeedb4a03f6cfb97eb0cbbceddf7628f540dbe08c20e1ddf7577c5e35",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Shanghai--China--Nov--6--2022-Pfizer-Sig.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Merck's deeper push into personalized cancer vaccines raises the competitive bar for Pfizer, BioNTech in biotech's fastest-growing race.",
                "category": "company",
                "datetime": 1787149875,
                "headline": "Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions"
              },
              {
                "id": 141253495,
                "url": "https://finnhub.io/api/news?id=ec53bf3cd9ee3dfc98465b108081a86c72c806699af67f35428e21d9f7be3993",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1787149800,
                "headline": "Let's uncover which stocks are experiencing notable gaps during today's session."
              },
              {
                "id": 141254919,
                "url": "https://finnhub.io/api/news?id=fc4875c5f56b1a197f0dd8974664c79d324fa885b862a9437949fdb57a942f96",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "",
                "category": "company",
                "datetime": 1787148555,
                "headline": "Moderna: Stock Surging On Cancer 'Vaccine' Breakthrough, I See More Volatility Ahead"
              },
              {
                "id": 141255462,
                "url": "https://finnhub.io/api/news?id=2b286492921519f765948c500cb6a5dbb1095b7ae86a0c930813419698ce748e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Logo-Pfizer-Inc--Is-An-American-Multinat.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) announced that their combination therapy of intismeran autogene and Keytruda showed positive recurrence-free survival results in melanoma patients.",
                "category": "company",
                "datetime": 1787147774,
                "headline": "Pfizer Stock Rises Wednesday: What's Going On?"
              },
              {
                "id": 141254760,
                "url": "https://finnhub.io/api/news?id=57e8f02c2967b0da83b1675ff236e9b421b988cb254b927caefd66a83d832158",
                "image": "https://image.cnbcfm.com/api/v1/image/108351716-17871603111787160309-47864338582-1080pnbcnews.jpg?v=1787160310&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "CNBC's Annika Kim Constantino reports on the increase in Moderna and Merck's share prices following the success of late stage trials of cancer vaccines.",
                "category": "company",
                "datetime": 1787146069,
                "headline": "Moderna and Merck shares surge"
              },
              {
                "id": 141254702,
                "url": "https://finnhub.io/api/news?id=85516d8c008355770031d63deb6a804ab3ae2903871b25ce3955544dea3beff6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Global-Stock-Market-Rally-And-Bullish-Pe.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Treasury's expanded long-bond buybacks knocked yields off 20-month highs and sank the dollar, aa gold soars.",
                "category": "company",
                "datetime": 1787145027,
                "headline": "Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today"
              },
              {
                "id": 141254712,
                "url": "https://finnhub.io/api/news?id=85690539df1f074b0141508ef60dd8720ee3792d4601920da3731c6695610e5e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "\n\n\n\nPlease click here for an enlarged chart of Moderna Inc (NASDAQ:MRNA).\n\n\n\nNote the following:\n\n\n\n\nThis article is about the big picture, not an individual stock.  The chart of MRNA stock is being used to illustrate",
                "category": "company",
                "datetime": 1787144995,
                "headline": "Investors Should Position For Humanoid Robot Boom—Here's A Picks-And-Shovels Play; First mRNA Cancer Vaccine Succeeds"
              },
              {
                "id": 141255445,
                "url": "https://finnhub.io/api/news?id=d8498a537dcb2597149bee64298a4bf7ebff471f668e068cab3989e7f02a3ac4",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Gainers\n\nZeroStack (NASDAQ:ZSTK) stock increased by 440.2% to $9.94 during Wednesday's regular session. The company's market cap stands at $4.4 million. \nTenon Medical (NASDAQ:TNON) shares moved upwards by",
                "category": "company",
                "datetime": 1787144750,
                "headline": "12 Health Care Stocks Moving In Wednesday's Intraday Session"
              },
              {
                "id": 141255466,
                "url": "https://finnhub.io/api/news?id=5a1e4b571ebfb2c67874e94c76a1594ee33097d7e1832173b68ce1b99dc89ea0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Biontech.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "BioNTech stock rises as Merck and Moderna report positive cancer vaccine data, highlighting its individualized mRNA cancer therapies.",
                "category": "company",
                "datetime": 1787143156,
                "headline": "Why Is BioNTech Stock Surging on Wednesday?"
              },
              {
                "id": 141253173,
                "url": "https://finnhub.io/api/news?id=c58a9c33229815012952c86e761766a0666280beddf95bea50271904dede2ca4",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the S&P500 stocks that are on the move in today's pre-market session.",
                "category": "company",
                "datetime": 1787142901,
                "headline": "Top S&P500 movers in Wednesday's pre-market session"
              },
              {
                "id": 141253141,
                "url": "https://finnhub.io/api/news?id=51fcf9114e5542f7d6be3f5d48a06b71d0cf00f79fba30c571ba73594b3c0e72",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.",
                "category": "company",
                "datetime": 1787142600,
                "headline": "Stay updated with the stocks that are on the move in today's pre-market session."
              },
              {
                "id": 141254113,
                "url": "https://finnhub.io/api/news?id=332a7e0719712ea75c9aa97201b73d49a69acc28bde48ac76686737f51f41954",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Merck & Co., Inc. hits all-time highs on positive Phase 3 melanoma vaccine data with Moderna. Click for this MRK update.",
                "category": "company",
                "datetime": 1787141995,
                "headline": "Merck Soars On Cancer Vaccine Trial Win With Moderna, More Upside Ahead"
              },
              {
                "id": 141254575,
                "url": "https://finnhub.io/api/news?id=9d7e9e7f859431ad4d509702fbb12e5043156a5da79a8c786fba99c1fedadb5f",
                "image": "https://image.cnbcfm.com/api/v1/image/108351657-17871557251787155722-47863276120-1080pnbcnews.jpg?v=1787155724&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Simon Baker, Rothschild & Co Redburn global biopharma research co-head, joins 'Squawk on the Street' to discuss Moderna and Merck shares surging after an experimental personalized cancer vaccine from both companies showed positive initial results in its first-ever late-stage trial.",
                "category": "company",
                "datetime": 1787141969,
                "headline": "Moderna, Merck cancer vaccine data 'a great result, but not entirely unexpected', says Simon Baker"
              },
              {
                "id": 141254046,
                "url": "https://finnhub.io/api/news?id=e0c310d135d9f52c015bce90d67f1cfcf65240fd61b70cb6898f48f7303a4fce",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Merck & Co., Inc. stock: After a 72% surge, valuation and FY2027 earnings expectations cap upside. Click for this MRK update.",
                "category": "company",
                "datetime": 1787141290,
                "headline": "Merck: Why Consolidation Looks Like The Next Move (Rating Downgrade)"
              },
              {
                "id": 141254252,
                "url": "https://finnhub.io/api/news?id=0d48955fcca03a8fd75d0cd981473894d6a3797ea0e54635ff7547ea3c380d51",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Lowes.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "The US stock market is up, with Nasdaq gaining 100 points. Dow up 0.39%, Nasdaq down 0.40%, S&P 500 up 0.50%. Health care shares gain 3.9%. Lowe's gains 5% after reporting mixed Q2 results. Estee Lauder up 16%. Mortgage applications fall 0.4%. Crude inventories rise for 3rd week.",
                "category": "company",
                "datetime": 1787140904,
                "headline": "Crude Oil Moves Higher; Lowe’s Shares Gain After Q2 Earnings"
              },
              {
                "id": 141254657,
                "url": "https://finnhub.io/api/news?id=b90096ab19b031c13d42cdaf1ef5498a1194b457759cbe4119982d998c2d4af2",
                "image": "https://image.cnbcfm.com/api/v1/image/108129624-1744234585970-gettyimages-2208760953-porzycki-modernai250409_nphLE.jpeg?v=1751282408&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1787139715,
                "headline": "Stocks making the biggest moves midday: Moderna, Pilgrim's Pride, Target, gold miners & more"
              },
              {
                "id": 141255468,
                "url": "https://finnhub.io/api/news?id=81075d72f0e1257e25c20e6c8887ff8193b9c2985bc25e6ce0491257afbe647b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Biochemistry--Scientist-Working-In-Labor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna and Merck announce success of personalized cancer therapy trial. MRNA stock surges, but MRK may be more important for investors.",
                "category": "company",
                "datetime": 1787137936,
                "headline": "Moderna's Cancer Vaccine Win Is Merck's Story Too"
              },
              {
                "id": 141255469,
                "url": "https://finnhub.io/api/news?id=20b77426df96ac5e8ca9049a7559277387b7db199336f0bc9ea5baf067e90b6e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna surged 151% on Phase 3 melanoma data with Merck, its biggest daily gain ever. Every Wall Street price target now sits below the price.",
                "category": "company",
                "datetime": 1787137606,
                "headline": "Moderna Stock Jumps 150%, Best Day Ever On Cancer Vaccine Win"
              },
              {
                "id": 141254576,
                "url": "https://finnhub.io/api/news?id=1b836e838eaedf2d33b698a7cbfdb205c0e53ea7218647fd41929187bc0ac8b2",
                "image": "https://image.cnbcfm.com/api/v1/image/108351559-17871495241787149521-47861858063-1080pnbcnews.jpg?v=1787149523&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "CNBC’s Annika Kim Constantino reports on Moderna after its experimental skin cancer vaccine with Merck showed success in a late-stage trial.",
                "category": "company",
                "datetime": 1787135546,
                "headline": "Moderna stock nearly doubles on new cancer vaccine results"
              },
              {
                "id": 141253626,
                "url": "https://finnhub.io/api/news?id=197e8c0d9d262c1b0887027aa7719c9b3fc37a633e76ff3691b8fb96e449251b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Estee-Lauder-Store-Sign-Close-up--Estee-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.",
                "category": "company",
                "datetime": 1787134092,
                "headline": "Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday"
              },
              {
                "id": 141254253,
                "url": "https://finnhub.io/api/news?id=03313eeaabcf2bedcca59174764220655bce57205ca99c5bc817c9f3f741c0ed",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Tallinn--Estonia---August-4th-2023---Scr.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "US stocks rise, Dow up 0.25%, NASDAQ up 0.10%, S&P 500 up 0.37%. Health care shares jump 3.1%; Target beats earnings, raises guidance.",
                "category": "company",
                "datetime": 1787133136,
                "headline": "Dow Gains Over 100 Points; Target Posts Upbeat Q2 Earnings"
              },
              {
                "id": 141254577,
                "url": "https://finnhub.io/api/news?id=15264f55e016123df482408b04b326a707d997d600a5b117bf24f202d6274f6e",
                "image": "https://image.cnbcfm.com/api/v1/image/108351449-17871406841787140679-47859846134-1080pnbcnews.jpg?v=1787140683&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Stephane Bancel, Moderna CEO, and Dr. Dean Li, Merck Research Laboratories president, join 'Squawk Box' to discuss details of an experimental personalized cancer vaccine that showed positive initial results in its first-ever late-stage trial, how the mRNA-based shot in combination with Merck’s immunotherapy Keytruda could serve as a new treatment option for melanoma, and more.",
                "category": "company",
                "datetime": 1787127335,
                "headline": "'An increased ability to be disease-free': Moderna CEO & Merck's Dr. Li on skin cancer vaccine trial"
              },
              {
                "id": 141254225,
                "url": "https://finnhub.io/api/news?id=077594d0076f02f799c4d06a512c1a636959b047d0027f911e019a9e824b4581",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Gainers\n\nTenon Medical (NASDAQ:TNON) stock rose 122.5% to $12.13 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.6 million. As per the news, the Q2 earnings report came",
                "category": "company",
                "datetime": 1787126824,
                "headline": "12 Health Care Stocks Moving In Wednesday's Pre-Market Session"
              },
              {
                "id": 141253685,
                "url": "https://finnhub.io/api/news?id=922be37f07b47e91ea7174e9e92f34c1bfd15cd3aaf2c1dd8ea5d241a7a28c8d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Cancer---Heart-Shape-To-Represent-Medica.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Merck and Moderna report positive Phase 3 results for their mRNA cancer therapy combined with Keytruda in melanoma patients.",
                "category": "company",
                "datetime": 1787125256,
                "headline": "Merck and Moderna Release Landmark Personalized Cancer Therapy Trial Success, Stocks Soar"
              },
              {
                "id": 141254578,
                "url": "https://finnhub.io/api/news?id=615b4c20357dff6843cbc3cc73731ea6690e792f225c7e9861c0c27946818b87",
                "image": "https://image.cnbcfm.com/api/v1/image/108222303-1762434766877-gettyimages-2235744008-CANADA_BIOMANUFACTURING.jpeg?v=1782501052&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1787124760,
                "headline": "Stocks making the biggest moves premarket: Moderna, Lowe's, Estee Lauder & more"
              },
              {
                "id": 141253686,
                "url": "https://finnhub.io/api/news?id=9e7199bb26b9b774c5f3aeda95d80147d50f2723df8632b6435bb1be0163af9a",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ:MRNA) today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with",
                "category": "company",
                "datetime": 1787122047,
                "headline": "Merck And Moderna Announce Topline Results From The Phase 3 Interpath-001 Trial Evaluating Adjuvant Treatment With Intismeran Autogene In Combination With KEYTRUDA In Patients With Completely Resected Stage IIB-IV Melanoma; At A Pre-specified Interim Analysis, Intismeran In Combination With KEYTRUDA As Adjuvant Therapy Demonstrated Statistically Significant And Clinically Meaningful Improvements In RFS And DMFS Compared To KEYTRUDA Alone"
              },
              {
                "id": 141254537,
                "url": "https://finnhub.io/api/news?id=334c77ccfcc478c591083e71da308c34954d0c0a902e0e5d6681a2890359dd45",
                "image": "https://image.cnbcfm.com/api/v1/image/108344537-1785853710278-Traders-Photo-20260803-KK-PRESS-013.jpg?v=1785853829&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "U.S. stocks jumped on Wednesday as Treasury yields fell after the Treasury Department announced an increased buyback operation for longer-term debt.",
                "category": "company",
                "datetime": 1787076144,
                "headline": "Dow rises as Treasury unveils plan to relieve bond market pressure: Live updates"
              },
              {
                "id": 141250739,
                "url": "https://finnhub.io/api/news?id=016d45c0ff50fb3b563059cb73a0060281769c9ee42ccf60d3d9b2bf5133307b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Free cash flow funds are having a moment, but many of the traditional FCF strategies miss the bigger picture and greater return potential. Victory Capital’s Mannik Dhillon breaks down how VFLO turned a forward-looking value investing strategy into one of the decade’s biggest ETF launches, all without a single Mag 7 stock, in this episode of Behind the Ticker.",
                "category": "company",
                "datetime": 1786992842,
                "headline": "Behind the Ticker: How VFLO Beats Growth at Its Own Game"
              },
              {
                "id": 141250736,
                "url": "https://finnhub.io/api/news?id=3b9a3068f3ef9b5b70da0fec87840377e53943fbd7bad879b88c577173fa7fbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.",
                "category": "company",
                "datetime": 1786957860,
                "headline": "FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax"
              },
              {
                "id": 141250737,
                "url": "https://finnhub.io/api/news?id=80ee134ed3f964c398598e7a869e109a3f365c5a4b0b3287810aba5a5d550b67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1786912140,
                "headline": "Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?"
              },
              {
                "id": 141250738,
                "url": "https://finnhub.io/api/news?id=f72b13afc2a0793fcf90639af87ac239fbe9b1fedd2d78f07c007ab798a83662",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.",
                "category": "company",
                "datetime": 1786727340,
                "headline": "3 Unprofitable Stocks We Keep Off Our Radar"
              },
              {
                "id": 141250740,
                "url": "https://finnhub.io/api/news?id=e0ef86744d5569b29dadfaece64664be10b237d1b6cf3b8174b06f2b6b17c24e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CEO Donn Casale outlines path to cash flow breakeven by 2027 while navigating slower-than-expected adoption and manufacturing headwinds.",
                "category": "company",
                "datetime": 1786683740,
                "headline": "ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ..."
              },
              {
                "id": 141201268,
                "url": "https://finnhub.io/api/news?id=fe0064a7c655ccaff3e90adfadaeb34185900cc00cbc37e1bc89b554127c7141",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus shareholders Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid nanoparticle (LNP) technology Achieved alignment with the U.S. Food and Drug Administration (FDA) on a proposed imdusir",
                "category": "company",
                "datetime": 1786534200,
                "headline": "Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update"
              },
              {
                "id": 141181051,
                "url": "https://finnhub.io/api/news?id=d9c163b5230fcbce2af75f65da199e675d0bba8f75a5b09c6bbcb0dcf09a881f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with a massive, non-dilutive liquidity boost while removing a significant overhang for […]",
                "category": "company",
                "datetime": 1786407501,
                "headline": "Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?"
              },
              {
                "id": 141175561,
                "url": "https://finnhub.io/api/news?id=4a562332d058d0f13b61c5826abf2babe330012f32e6d3088d4724981c07710d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.",
                "category": "company",
                "datetime": 1786377702,
                "headline": "FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market"
              },
              {
                "id": 141175274,
                "url": "https://finnhub.io/api/news?id=d748c649d767517901cdba8efff57aa3b14812c64bab4e2a312033b7876c68b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "On this episode of Stock Movers: - RocketLab (RKLB) shares are higher this morning after rising Friday, following earnings from SpaceX last week. - Moderna (MRNA) shares are moving after last week's news that its mRNA flu shot won US approval in an FDA turnaround. - Intel (INTC) shares are moving after the company said it will be offering $15 billion in common stock, taking advantage of renewed interest in its business prospects during the artificial intelligence data center boom.",
                "category": "company",
                "datetime": 1786374977,
                "headline": "RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers"
              },
              {
                "id": 141177769,
                "url": "https://finnhub.io/api/news?id=9fc13a6f1f120c3d5712dbe2d97e5f0cc6fae4550b2463703edb7b77d3ef9238",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "https://youtu.be/H_RititNE8U",
                "category": "company",
                "datetime": 1786374019,
                "headline": "Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children"
              },
              {
                "id": 141173955,
                "url": "https://finnhub.io/api/news?id=8f8a6c94e14cda994096b4ea274ea3ef41e64e688ce7867132f30f540487144b",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
                "category": "company",
                "datetime": 1786365301,
                "headline": "Get insights into the top movers in the S&P500 index of Monday's pre-market session."
              },
              {
                "id": 141173544,
                "url": "https://finnhub.io/api/news?id=b941f9d258011d9774e73dcaf43578d9a7d9b0d74402a64bd442dab3aca6617f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241965815/image_2241965815.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna (MRNA) valuation in focus: weak Q2, cash outlook, FDA win for mFLUSIVA, pipeline risks and sales hurdles.",
                "category": "company",
                "datetime": 1786347053,
                "headline": "Moderna: I'm Still On Sell, But Here's What Would Change My Mind"
              },
              {
                "id": 141155648,
                "url": "https://finnhub.io/api/news?id=d9e90214fe03d4767733465ade546ee88cd239ba15f2c7dd159de8382fbf8fcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Net loss improved 5% on international partnerships and manufacturing gains.",
                "category": "company",
                "datetime": 1786156376,
                "headline": "Moderna (MRNA) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141150616,
                "url": "https://finnhub.io/api/news?id=97cc30b60f13c7af214f0c0afb17997cc515ad12a36ad63fdf4d3ec954ca3f5c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1786129501,
                "headline": "Stay informed with the top movers within the S&P500 index on Friday."
              },
              {
                "id": 141148910,
                "url": "https://finnhub.io/api/news?id=9bdba43fcab22b2cbe6b2e92788d4e69dd55e6b163385f9dbbc531c0004beafd",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.",
                "category": "company",
                "datetime": 1786120501,
                "headline": "Top S&P500 movers in Friday's session"
              },
              {
                "id": 141148372,
                "url": "https://finnhub.io/api/news?id=3746977f62a3f52bb06e4337c1c4785d5648c76514f4be482ffcb7b77884dadf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.",
                "category": "company",
                "datetime": 1786113900,
                "headline": "Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones"
              },
              {
                "id": 141147242,
                "url": "https://finnhub.io/api/news?id=6e64abe7f35a4500597d447a501575e2d06b96289d593836ace76e012eb9c542",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NasdaqGS:MRNA) has initiated a Phase 1 clinical trial in Canada for its investigational mRNA vaccine targeting Bundibugyo ebolavirus. The program addresses a strain of Ebola that currently has no approved vaccine and is positioned as part of Moderna's broader infectious disease portfolio. The trial involves collaboration with CEPI and Canadian public health authorities, with a stated focus on access for low and middle income countries. This kind of targeted vaccine work highlights...",
                "category": "company",
                "datetime": 1786108318,
                "headline": "Moderna (MRNA) Starts Phase 1 Canada Trial For Bundibugyo Ebola mRNA Vaccine"
              },
              {
                "id": 141158420,
                "url": "https://finnhub.io/api/news?id=815d119cb70a6c941f8f11ff450732683edd713eff6a2a1cb3a31627cf26ab5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moby summary of Roivant Sciences Ltd.'s Q1 2026 earnings call",
                "category": "company",
                "datetime": 1786105800,
                "headline": "Roivant Sciences Ltd. Q1 2026 Earnings Call Summary"
              },
              {
                "id": 141146398,
                "url": "https://finnhub.io/api/news?id=18887605dd87cf9a26e6068ca922418b72cc2859e699a008ce3f08ba711e5700",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie",
                "category": "company",
                "datetime": 1786100637,
                "headline": "Roivant Sciences Q1 Earnings Call Highlights"
              },
              {
                "id": 141145823,
                "url": "https://finnhub.io/api/news?id=7eeb3f1c50ce29db097d3f6725f03f44eba5c394319c532ac14e3a101602bae7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Dublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The \"Global Influenza Vaccine Market: 2026 Edition\" has been added to ResearchAndMarkets.com's offering. The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, expanding at a compound annual growth rate of approximately 7% between 2025 and 2030. Market growth is being supported by rising public health awareness, an expanding geriatric population, government immunization programs, recu",
                "category": "company",
                "datetime": 1786096440,
                "headline": "Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players"
              },
              {
                "id": 141149503,
                "url": "https://finnhub.io/api/news?id=6870e18d4d437dc9735084b362356556adcff40b5e1f22342eb3f986f385884a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The company says it expects to have mFlusiva ready for the upcoming 2026-2027 flu season, which runs from roughly October to May.",
                "category": "company",
                "datetime": 1786075260,
                "headline": "For Moderna’s Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off"
              },
              {
                "id": 141140831,
                "url": "https://finnhub.io/api/news?id=949f85a6afc00c6caf0a54c21311022fb79bb3057102c12440934d1547c1fde0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) is back in focus after the US Food and Drug Administration approved mFLUSIVA, the company’s mRNA based flu vaccine for adults aged 50 and over, sparking renewed interest in the stock. See our latest analysis for Moderna. The FDA approval of mFLUSIVA comes after a period of sharp swings in Moderna’s share price, with a 1-month share price return down 31.23% but a year to date share price return up 82.29%. At the same time, the 1-year total shareholder return of 110.61% contrasts...",
                "category": "company",
                "datetime": 1786050946,
                "headline": "Moderna (MRNA) Wins Flu Vaccine Approval, Is It Fully Priced?"
              },
              {
                "id": 141140832,
                "url": "https://finnhub.io/api/news?id=e5f8332b54bd5057e2f02f6f1a1b257c2fc58dcb8da287186370ec5fdd7711c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock fell Thursday after the Food and Drug Administration approved its mRNA-based flu shot, now called mFlusiva.",
                "category": "company",
                "datetime": 1786046999,
                "headline": "Moderna Dives Despite Hard-Fought FDA Win; Will Its Sprint Restart?"
              },
              {
                "id": 141140833,
                "url": "https://finnhub.io/api/news?id=377f7db9ee1ccb19cd52649e1d7a25544adaddf1cfc94bd7713c496aee749f28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt",
                "category": "company",
                "datetime": 1786043059,
                "headline": "Immunovant Q1 Earnings Call Highlights"
              },
              {
                "id": 141140972,
                "url": "https://finnhub.io/api/news?id=4a97cb2c93a9c2dbae51257069fddd4c5e262195e7fd25604102e666ed4523af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Roivant Sciences Ltd (ROIV) reports robust financials and key clinical milestones, including the brepocitinib launch and Moderna settlement, while navigating pipeline uncertainties.",
                "category": "company",
                "datetime": 1786042967,
                "headline": "Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong ..."
              },
              {
                "id": 141142439,
                "url": "https://finnhub.io/api/news?id=3fc6f65f8064897a597e60b3b7e44becfb2dae2f04dd5388984b98c1ca27162c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!",
                "category": "company",
                "datetime": 1786039280,
                "headline": "MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine"
              },
              {
                "id": 141137506,
                "url": "https://finnhub.io/api/news?id=64c4411f3130056dc8d8567d24917e366f3e522ac238fc8789f56ebd3c04e68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The approval makes mFLUSIVA Moderna’s fourth FDA-cleared product and the first messenger RNA-based flu vaccine.",
                "category": "company",
                "datetime": 1786036804,
                "headline": "MRNA Stock Pares Gains Despite FDA Green Light For First mRNA Flu Vaccine — But Retail Cheers Pivot Beyond COVID"
              },
              {
                "id": 141137139,
                "url": "https://finnhub.io/api/news?id=ea8cdd716db11d8a39e4d0739426a07c1de0c0ad54f47da59b9be87c2a541437",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Up to 911.5 million shares of SpaceX that are held by insiders and early investors are available to trade beginning Thursday.",
                "category": "company",
                "datetime": 1786030620,
                "headline": "SpaceX, Honeywell Aerospace, Sandisk, D-Wave, Datadog, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141135733,
                "url": "https://finnhub.io/api/news?id=26f7eff393b66776d3e8191329ee5ab9cc2932d8155f77c196e7b20729ff5f3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.",
                "category": "company",
                "datetime": 1786027860,
                "headline": "Moderna Just Got FDA Clearance for Flu Vaccine. The Stock Slips."
              },
              {
                "id": 141135734,
                "url": "https://finnhub.io/api/news?id=f58ddb6312b7b86c7ed90e4e46756b27cb0e6cf00e4f09253a3da1417aec8d3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock wavered Thursday after the Food and Drug Administration approved its mRNA-based flu shot, now called mFlusiva.",
                "category": "company",
                "datetime": 1786025636,
                "headline": "Moderna Wavers Despite Hard-Fought FDA Win; Will Its Sprint Restart?"
              },
              {
                "id": 141136784,
                "url": "https://finnhub.io/api/news?id=36d69d69a81b7a045aaeee6e062977c043dbbaf4dc639a27c093334a34b257a6",
                "image": "https://image.cnbcfm.com/api/v1/image/107249878-1685705682614-gettyimages-1369197035-366a7104_20d35d56-4f16-4497-b339-40f06443ab58.jpeg?v=1692790091&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Here are some of the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1786023113,
                "headline": "Stocks making the biggest moves midday: UMW Holdings, Honeywell Aerospace, Macom, Peloton & more"
              },
              {
                "id": 141134031,
                "url": "https://finnhub.io/api/news?id=842cfcc89663b00eb959048a1e078321d2fab8f79c6fca68cf2d767b324e8670",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Memory stocks falter after guidance from Sandisk and Western Digital fails to meet Wall Street’s lofty expectations.",
                "category": "company",
                "datetime": 1786020780,
                "headline": "Sandisk, Western Digital, D-Wave, IonQ, AppLovin, Datadog, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141133671,
                "url": "https://finnhub.io/api/news?id=91c0194f617b9ce222be9f2c00c78db94f28ee70b970fb642bc4031e439b6786",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
                "category": "company",
                "datetime": 1786019701,
                "headline": "What's going on in today's pre-market session: S&P500 movers"
              },
              {
                "id": 141134298,
                "url": "https://finnhub.io/api/news?id=b4a6f17d531bbac944a535fa8fc8e7adca7c998ed815483b16c04d66be18dfd9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.",
                "category": "company",
                "datetime": 1786019160,
                "headline": "Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future"
              },
              {
                "id": 141134100,
                "url": "https://finnhub.io/api/news?id=fb525e1bdb7f00515828cb9ade2d230c825685eac77ea77d7ad7b7ad1d42b335",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "News of the day for Aug. 6, 2026",
                "category": "company",
                "datetime": 1786018980,
                "headline": "5 Things to Know Before the Stock Market Opens on Thursday"
              },
              {
                "id": 141136785,
                "url": "https://finnhub.io/api/news?id=7ea069109bf4e757834afdeff1a9a425be08ac6ee22c5a85cfd4b58d0117f3f1",
                "image": "https://image.cnbcfm.com/api/v1/image/108346049-17860291021786029100-47613163649-1080pnbcnews.jpg?v=1786029101&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "CNBC’s Annika Kim Constantino joins 'Squawk on the Street' to discuss the FDA approving Moderna's mRNA flu vaccine.",
                "category": "company",
                "datetime": 1786016123,
                "headline": "FDA approves Moderna mRNA flu shot"
              },
              {
                "id": 141138228,
                "url": "https://finnhub.io/api/news?id=aa8fef1bf003f6a68dc7428f865d74ce3a7df9bc180ec3376cfb2973c05af540",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/06/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna receives FDA approval for mFLUSIVA, a new seasonal flu vaccine for adults 50 and older, launching for the 2026-2027 virus season.",
                "category": "company",
                "datetime": 1786014383,
                "headline": "Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine"
              },
              {
                "id": 141133395,
                "url": "https://finnhub.io/api/news?id=9ad6e18b59b59ba95ea3c6a80942b33d39456293eef3c1776e10387382305278",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (NIU) expected in the second half of calendar year 2026First patients enrolled in the Phase 3 study of brepocitinib in cutaneous sarcoidosis (CS), with topline data expected in calendar year 2028; enrollment in Part 1 of the Phase 2b/3 study in lichen planopilaris (LPP) is progressing wellIMVT-1402 pr",
                "category": "company",
                "datetime": 1786014000,
                "headline": "Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update"
              },
              {
                "id": 141133200,
                "url": "https://finnhub.io/api/news?id=2a06843db7e338a41ee0c8ff68629f74c4a4442c3d3be25a55a67acd049203bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Memory stocks falter after guidance from Sandisk and Western Digital fails to meet the market’s sky-high expectations.",
                "category": "company",
                "datetime": 1786012920,
                "headline": "Sandisk, AppLovin, Moderna, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141133397,
                "url": "https://finnhub.io/api/news?id=c46773845d5cedef8aa5bfb3688c68aebb3d3eff8143231a9672fd0b38c0a086",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NASDAQ:MRNA) announced on Thursday that the U. S.",
                "category": "company",
                "datetime": 1786010836,
                "headline": "Moderna secures FDA approval for its first mRNA influenza vaccine"
              },
              {
                "id": 141136544,
                "url": "https://finnhub.io/api/news?id=9afbaad8619c7e88d0327fc9f16e16408a9548631ed15d11289a190b25b1d25d",
                "image": "https://image.cnbcfm.com/api/v1/image/108222317-1762435648172-gettyimages-2238075663-PELOTON_PRODUCTS.jpeg?v=1778073972&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are the stocks posting the largest moves in the premarket.",
                "category": "company",
                "datetime": 1786002650,
                "headline": "Stocks making the biggest moves premarket: Zillow, Peloton, Sandisk, Moderna & more"
              },
              {
                "id": 141132481,
                "url": "https://finnhub.io/api/news?id=ccf8ab372c3c2820cf388c4d522bcf3f278eb5c85ac3ba8813a56552ab68eb78",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "2026-08-06. The following slide deck was published by Moderna, Inc.",
                "category": "company",
                "datetime": 1785992836,
                "headline": "Moderna, Inc. 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141130974,
                "url": "https://finnhub.io/api/news?id=901409672929f92426a10f23decc4037b8173f778a55dc4b116dd6f1d4b8ab60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswire / August 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) ...",
                "category": "company",
                "datetime": 1785982500,
                "headline": "Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA"
              },
              {
                "id": 141120470,
                "url": "https://finnhub.io/api/news?id=ea02b890c98468dfcb6a3daf4a57e1155c97d4a78bb7d6052414b48250e69e07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc. (NASDAQ:MRNA) stock rose in Wednesday premarket trading after gaining 3.4% in the previous session, as investors reacted to the company’s latest progress in expanding its infectious disease pipeline with an investigational Ebola vaccine. Moderna Begins Phase 1 Trial For Ebola Vaccine Moderna has initiated a Phase 1 clinical trial evaluating mRNA-1469, an investigational vaccine designed to prevent Bundibugyo ebolavirus disease, for which no licensed vaccines currently exist. The stu",
                "category": "company",
                "datetime": 1785923262,
                "headline": "Moderna Advances Ebola Vaccine Into Human Testing"
              },
              {
                "id": 141122783,
                "url": "https://finnhub.io/api/news?id=1359891d2147dc7f7a10d4f13c8d3ac38bb25ee5ac8b1673eacca3cd7736c12a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Despite Moderna's stellar outperformance over the past year, Wall Street analysts remain cautious about the stock's longer-term prospects.",
                "category": "company",
                "datetime": 1785920357,
                "headline": "Are Wall Street Analysts Predicting Moderna Stock Will Climb or Sink?"
              },
              {
                "id": 141116462,
                "url": "https://finnhub.io/api/news?id=878b3f780bc1eaafe209c8223de498ae780eeb977329935233ac5b0317c54423",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "President Donald Trump discussed efforts to de-escalate US-Iran tensions with Qatari Emir Tamim bin Hamad Al Thani.",
                "category": "company",
                "datetime": 1785883534,
                "headline": "US Stock Futures Flat After S&P500, Dow End At Record Highs On Strong Earnings, Easing Geopolitical Concerns — PLTR, AZN, CMG, MRNA In Focus"
              },
              {
                "id": 141113095,
                "url": "https://finnhub.io/api/news?id=495a9f3d43e0cd55a8d639e8a0d979bfd84f00514344190add89cc6bd6820f3f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "These innovative biotech companies should reap the benefits of their breakthroughs.",
                "category": "company",
                "datetime": 1785871200,
                "headline": "Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does"
              },
              {
                "id": 141114899,
                "url": "https://finnhub.io/api/news?id=cc3466133ae9d0222d3d3b5b33ac9866171e629a6604cb4942181fac631f1c58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.",
                "category": "company",
                "datetime": 1785870060,
                "headline": "Moderna Stock Jumps on Hope for Breakthrough Ebola Vaccine—Key Word Being Hope"
              },
              {
                "id": 141112040,
                "url": "https://finnhub.io/api/news?id=f887021c29724e46fcc0203820936f8be8f20dc6727f6d7ef68a7d798b42c9e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna began a Phase 1 clinical trial of its experimental vaccine mRNA-1469 targeting the Bundibugyo strain of Ebola virus.",
                "category": "company",
                "datetime": 1785862022,
                "headline": "Moderna Doses First Participants In Ebola Vaccine Trial Ahead Of Key FDA Decision On Flu Shot"
              },
              {
                "id": 141111706,
                "url": "https://finnhub.io/api/news?id=9c275454cff15b564fb226211e33cf6b1539659100c3f312e3ee5e7e9a51b3c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.",
                "category": "company",
                "datetime": 1785861300,
                "headline": "Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine"
              },
              {
                "id": 141110326,
                "url": "https://finnhub.io/api/news?id=4fd7e9368dbe354b4538ff8c587b416efbf166d29f2bb2e18bc5e270d8f7c682",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our expanded collaboration with the Coalition for Epidemic Preparedness ...",
                "category": "company",
                "datetime": 1785855600,
                "headline": "Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus"
              },
              {
                "id": 141108636,
                "url": "https://finnhub.io/api/news?id=086305ba800b422dd0362144823856dc37cb6f97965ef7da8b38ac317f13d03a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.",
                "category": "company",
                "datetime": 1785844260,
                "headline": "Merck Stock Rises as Wall Street Looks Past Earnings Guidance Cut"
              },
              {
                "id": 141113874,
                "url": "https://finnhub.io/api/news?id=831816d0de79a48cf7d579cacb11d9de6477658ba44b3963cc520f628cbd3ce7",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna, Inc. (NASDAQ:MRNA) today announced that following Health Canada's authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, the",
                "category": "company",
                "datetime": 1785841353,
                "headline": "Moderna Vaccinates First Patients In Its Phase 1 Clinical Trial Of mRNA-1469 To Treat Bundibugyo Ebolavirus Following Health Canada Approval"
              },
              {
                "id": 141107778,
                "url": "https://finnhub.io/api/news?id=e338f789de4326b6d7e3998fec35e4fc4c9616d1e576b241f6769d4026226e43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.",
                "category": "company",
                "datetime": 1785840240,
                "headline": "Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?"
              },
              {
                "id": 141103086,
                "url": "https://finnhub.io/api/news?id=13f4ed8945887472491b9646b5fbac7e532d18f83a28e9a7f1baec450afd66f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.",
                "category": "company",
                "datetime": 1785792372,
                "headline": "MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading"
              },
              {
                "id": 141101221,
                "url": "https://finnhub.io/api/news?id=de4bfb820e8479cd503c5376fbd8bd409e7c3bb9d0d0b0453ad1b15abd3bf26e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) is facing several vaccine headwinds in the near to medium term, particularly for its",
                "category": "company",
                "datetime": 1785774052,
                "headline": "Moderna Facing Several Vaccine Headwinds in Near, Medium Term, RBC Says"
              },
              {
                "id": 141103670,
                "url": "https://finnhub.io/api/news?id=3296d2afc22fac4a9f1853d2534e5c8501f04e2ba9bc27cdf6f1941ea71c70d5",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Citigroup  analyst Geoff Meacham   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $41 to $60.",
                "category": "company",
                "datetime": 1785768145,
                "headline": "Citigroup Maintains Neutral on Moderna, Raises Price Target to $60"
              },
              {
                "id": 141090085,
                "url": "https://finnhub.io/api/news?id=cb92c7695a573ae9a1aa735a7a6b602d023a0f40809fbd6cc67e8b95a4057c73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna reported its Q2 update alongside news that its lead norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, so the trial will continue for further evaluation. The company is awaiting an FDA decision on its seasonal influenza vaccine, mFLUSIVA, which is expected by early August. Management paired these pipeline updates with Q2 results that were ahead of expectations and a revised outlook for operating expenses. For investors watching...",
                "category": "company",
                "datetime": 1785625773,
                "headline": "Moderna (MRNA) Faces Norovirus Setback As MFLUSIVA FDA Decision Nears"
              },
              {
                "id": 141120471,
                "url": "https://finnhub.io/api/news?id=ff40d06048e0c470e2da9c0a69160f12f39015cae1263d96a940b8c8f540128f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moby summary of Moderna, Inc.'s Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785587400,
                "headline": "Moderna, Inc. Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141087207,
                "url": "https://finnhub.io/api/news?id=79e77c460a159b12b5fdb784f7c44efc0b1aefa6cfa1fa600377134cf99ef33f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "After a whipsaw end to the month, the stock market’s decline was highlighted by the worst month for chip stocks in 24 years.",
                "category": "company",
                "datetime": 1785532200,
                "headline": "S&P 500 ends with its first July decline since 2014. Here are the stocks that led the selloff."
              },
              {
                "id": 141081727,
                "url": "https://finnhub.io/api/news?id=0e6b217ea0b704ea595a10ac7e41a3d97c4c6866d4197a0c10d8a2c6a799ae5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc (MRNA) exceeds Q2 revenue guidance and advances key vaccines, but faces delays in norovirus trial and oncology readouts.",
                "category": "company",
                "datetime": 1785524454,
                "headline": "Moderna Inc (MRNA) (Q2 2026) Earnings Call Highlights: Revenue Beat and Pipeline Progress Amid ..."
              },
              {
                "id": 141081549,
                "url": "https://finnhub.io/api/news?id=8e5807917ad3962f527a25faccd33954fa586c6c2a18376f52be2d06d6f439e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.",
                "category": "company",
                "datetime": 1785521040,
                "headline": "MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback"
              },
              {
                "id": 141082486,
                "url": "https://finnhub.io/api/news?id=21fe1895d9ac65bb599d35683c6e6f056e64d3d7c4837373bce0b5341710b638",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2204956103/image_2204956103.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "BioNTech trades near cash value; the oncology pipeline looks undervalued. Click here to read more about BNTX.",
                "category": "company",
                "datetime": 1785520130,
                "headline": "BioNTech: The Market Is Offering A 17-Program Oncology Pipeline For Almost Free"
              },
              {
                "id": 141079232,
                "url": "https://finnhub.io/api/news?id=159623b026e0607fa80577aa52ddf408b57d1f135c78429e79947233fe70e49b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The company topped Wall Street loss estimates, but its norovirus vaccine missed a key trial goal, sending shares lower",
                "category": "company",
                "datetime": 1785508239,
                "headline": "Moderna Q2 earnings beat estimates as norovirus vaccine stumbles"
              },
              {
                "id": 141079011,
                "url": "https://finnhub.io/api/news?id=97d9e222b054c1476b225754963b5acf752f93c797fd5c1c65e3d242e6a2ec01",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna  posted a narrower per-share loss in its latest quarter, but shares traded slightly lower as the company’s earnings report highlighted the drugmaker’s ongoing struggle to break away from its pandemic-driven business model.  Moderna  posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year.  The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.",
                "category": "company",
                "datetime": 1785506820,
                "headline": "Moderna Stock Has Doubled This Year. Can Earnings Keep the Rally Alive?"
              },
              {
                "id": 141079234,
                "url": "https://finnhub.io/api/news?id=c40ab8e955d13abb37b786cfe5287080bfadd5793abe8221034d396f5ee3dca9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases. The company posted a net loss of $782 million, or $1.97 per sha",
                "category": "company",
                "datetime": 1785506644,
                "headline": "Moderna Q2 Earnings Call Highlights"
              },
              {
                "id": 141077642,
                "url": "https://finnhub.io/api/news?id=3223cbf246df2f33c69539037f774a50260cd33d10286f045a518ad8062cad57",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Discover the top S&P500 movers in Friday's pre-market session and stay informed about market dynamics.",
                "category": "company",
                "datetime": 1785501301,
                "headline": "Get insights into the top movers in the S&P500 index of Friday's pre-market session."
              },
              {
                "id": 141078119,
                "url": "https://finnhub.io/api/news?id=6d37bef2f33c33b4f6b6bfdf56597d464c5ea9a0b5ac0b25c4bcdeebf542418b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785499801,
                "headline": "Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates"
              },
              {
                "id": 141079288,
                "url": "https://finnhub.io/api/news?id=fd73d347dd147f3649ce5c5b73510e7caedfd46a2f910fb34cf75b4a3016c588",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna, Inc. (MRNA) Q2 2026 Earnings Call July 31, 2026 8:00 AM EDTCompany ParticipantsLavina Talukdar - Senior VP & Head of Investor RelationsStéphane...",
                "category": "company",
                "datetime": 1785499402,
                "headline": "Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141077109,
                "url": "https://finnhub.io/api/news?id=f16d5a2dc9b6a4824034e9a6c0d771a4a457d491209a6f45740cd61bdbd2cfc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The benchmark US stock measures were tracking in the green before the open Friday as Amazon's (AMZN)",
                "category": "company",
                "datetime": 1785498389,
                "headline": "Stocks Rise Pre-Bell as Amazon Results Lift AI Trade Sentiment"
              },
              {
                "id": 141077360,
                "url": "https://finnhub.io/api/news?id=feadc898c39604ac58b85c95f9d3176aeea761452bbb6bc4f69f6cae69fdbaa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna  posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway.  Moderna  posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year.  The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.",
                "category": "company",
                "datetime": 1785497160,
                "headline": "Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?"
              },
              {
                "id": 141087997,
                "url": "https://finnhub.io/api/news?id=4caacbfb9100f8c9139b37721bfee97ef3989fd0afb2ded093e82f4cfa495084",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/31/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna (MRNA) Q2 Earnings: Beat estimates with $145M in sales and a $1.97 EPS loss. Reaffirms 2026 sales guidance.",
                "category": "company",
                "datetime": 1785496990,
                "headline": "Moderna Burns Cash, Suffers Fresh Vaccine Setback"
              },
              {
                "id": 141077361,
                "url": "https://finnhub.io/api/news?id=a0f0c5f8e5d5760b0b477b139ba5c2d18c0c6adf092582f7ad9a7b5a721d8a67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.1% year on year to $145 million. Its GAAP loss of $1.97 per share was 4.2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785496443,
                "headline": "Moderna (NASDAQ:MRNA) Beats Expectations in Q2 CY2026"
              },
              {
                "id": 141077362,
                "url": "https://finnhub.io/api/news?id=dc1dfb1ce678963e373dc8acf68f295f9fe51a03af150eb0eac84b7190ec20b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97) Reiterates plan to deliver up to 10% revenue growth in 2026 Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous ...",
                "category": "company",
                "datetime": 1785495600,
                "headline": "Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates"
              },
              {
                "id": 141078331,
                "url": "https://finnhub.io/api/news?id=ac530d31eb48c583c6b8bbc1b91343789c5a8e500ff7be600e75e89b17e3ab3b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2186886491/image_2186886491.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna is navigating a post-COVID transition, shifting focus to a diversified vaccine and therapeutics pipeline amid weak demand. Read more on MRNA stock here.",
                "category": "company",
                "datetime": 1785493846,
                "headline": "Moderna Q2: Weak Revenue, Strong Pipeline - Here's What Matters Now"
              },
              {
                "id": 141079909,
                "url": "https://finnhub.io/api/news?id=a5a7705f07d9b232c16355122cc3473a9188034e2f288c75be991d6c3a809f66",
                "image": "https://image.cnbcfm.com/api/v1/image/108313757-1780058150187-gettyimages-2275740460-TFSPI_14052026-5453.jpeg?v=1780058175&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1785483901,
                "headline": "Stocks making the biggest moves premarket: Replimune, Chevron, Apple, Amazon, Moderna & more"
              },
              {
                "id": 141078474,
                "url": "https://finnhub.io/api/news?id=4924c4d4a3733c4c77af4a5b8d10596bddf5c95e5af21a48d5f630a464a94aef",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna (NASDAQ:MRNA) affirms FY2026 sales outlook from $2.138 billion to $2.138 billion vs $2.089 billion estimate.",
                "category": "company",
                "datetime": 1785481264,
                "headline": "Moderna Affirms FY2026 Sales Guidance of $2.138B vs $2.089B Est"
              },
              {
                "id": 141068643,
                "url": "https://finnhub.io/api/news?id=6f0b72b80f20cb1734cc4c653ea213e50f7ebf7604dda827380b5c51cba56cfa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "There are fresh signs that fusion power startup Commonwealth Fusion Systems will list in the next two to three years.",
                "category": "company",
                "datetime": 1785426336,
                "headline": "When will fusion power startup Commonwealth Fusion Systems go public?"
              },
              {
                "id": 141067188,
                "url": "https://finnhub.io/api/news?id=cc026c98fea4324709a01e8a4a3c5c612c09d3cd2a3302964a661cc3b6940004",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results this Friday before market hours. Here’s what investors should know.",
                "category": "company",
                "datetime": 1785421262,
                "headline": "Moderna (MRNA) Q2 Earnings: What To Expect"
              },
              {
                "id": 141057077,
                "url": "https://finnhub.io/api/news?id=4a73e97bf16c01c4763ccc1ac48e9fce315900a166893fe20d536f40103001c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.",
                "category": "company",
                "datetime": 1785344580,
                "headline": "Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?"
              },
              {
                "id": 141056001,
                "url": "https://finnhub.io/api/news?id=42d1ace2654ba2bd9f203d862d7fec3bb81edcd8e97e9999a70c3c7f1e26b553",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock has delivered a strong 70.9% gain over the past year, but the longer track record and current valuation checks suggest the shares are not clearly priced as a bargain right now. Over five years, Moderna shareholders have seen the stock decline 85.6%, which puts the recent rebound in a much longer and still challenging context. Progress on the mRNA cancer program, including the recent Phase 1 trial start for mRNA-4200, can support sentiment on Moderna’s growth potential. At the...",
                "category": "company",
                "datetime": 1785341341,
                "headline": "Moderna (MRNA) Stock May Be Overvalued After Cancer Trial Start"
              },
              {
                "id": 141054570,
                "url": "https://finnhub.io/api/news?id=7a062cb0f57e72f12ca133cba9778cd83bcd77192d4de1dd4142cf922f41d010",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The year 2026 has turned into a pivotal year for the biotech capital markets. Venture funding for biotech firms reached $9.1 billion in the first half of the year, the highest total since 2022, with 38 acquisitions being completed over the same period, marking the sector’s greatest M&A pace in at least seven years. Underneath […]",
                "category": "company",
                "datetime": 1785337503,
                "headline": "Moderna Stock Has Doubled in 2026, But Wall Street Still Isn’t Convinced"
              },
              {
                "id": 141053279,
                "url": "https://finnhub.io/api/news?id=a0f0df1b96fb612ea00f606fa308ad08c08fff23339b1ab08cadc9cee3998d9d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In recent months, Moderna reported a very large year-on-year Q1 revenue increase that surpassed analyst expectations, secured two European approvals including the world’s first flu plus COVID combination vaccine mCOMBRIAX, and began a pivotal Phase 3 trial for its lung cancer candidate intismeran. This combination of new product approvals and late-stage oncology pipeline progress highlights Moderna’s effort to broaden its business well beyond its COVID-19 franchise. We’ll now examine how the...",
                "category": "company",
                "datetime": 1785330585,
                "headline": "Why Moderna (MRNA) Is Down 6.5% After Europe Clears Its First Flu-COVID Combo Vaccine"
              },
              {
                "id": 141052277,
                "url": "https://finnhub.io/api/news?id=2625622a16fd23e22e1bea637d0a6ab5014872dcc8587d4bdb5968cc04ba868c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.",
                "category": "company",
                "datetime": 1785326417,
                "headline": "3 Biotech Stocks With Massive Upside to Buy Before August Starts"
              },
              {
                "id": 141049147,
                "url": "https://finnhub.io/api/news?id=847f022feb42bf4d47a784124e1326cc42350ccd7a0f939c17b8e3547748713d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 14.3% over the past six months while the S&P 500 was up 6.3%.",
                "category": "company",
                "datetime": 1785285902,
                "headline": "1 Healthcare Stock to Keep an Eye On and 2 We Avoid"
              },
              {
                "id": 141045629,
                "url": "https://finnhub.io/api/news?id=9896d38833b64101df2a2a0f1f49cf45257fda96b8dd51902d04c599480ea14a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has already surged more than 80% in 2026, but two major events packed into the next two weeks could either cement that rally or unravel it fast.",
                "category": "company",
                "datetime": 1785255709,
                "headline": "2 Major Reasons to Buy Moderna Stock Before July 31"
              },
              {
                "id": 141039020,
                "url": "https://finnhub.io/api/news?id=8fd1782ce05250991501094467121195fe3381f0424a31fb4a32d1bbfbab84c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at therapeutics stocks, starting with Moderna (NASDAQ:MRNA).",
                "category": "company",
                "datetime": 1785200942,
                "headline": "Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks"
              },
              {
                "id": 141038245,
                "url": "https://finnhub.io/api/news?id=47f74155c62b90bd68e5ca30079eeafceadd9ffd98e1024e5dcf70f7e7908c58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In the most recent trading session, Moderna (MRNA) closed at $55.63, indicating a +2.89% shift from the previous trading day.",
                "category": "company",
                "datetime": 1785189004,
                "headline": "Moderna (MRNA) Laps the Stock Market: Here's Why"
              },
              {
                "id": 141037355,
                "url": "https://finnhub.io/api/news?id=39fec9f047840672f1016880d7063a68767b5c8011a8796005ee76165a2717a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's stock recently hit a new 52-week high after receiving positive news surrounding one of its vaccines.",
                "category": "company",
                "datetime": 1785183747,
                "headline": "After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?"
              },
              {
                "id": 141036351,
                "url": "https://finnhub.io/api/news?id=5b184e2138a7cf1b916297cca94bbf2d1b1ca16fe8b25b8f27bd6fce1dd88ee6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Moderna (NASDAQ:MRNA) and its peers.",
                "category": "company",
                "datetime": 1785177902,
                "headline": "Therapeutics Stocks Q1 Highlights: Moderna (NASDAQ:MRNA)"
              },
              {
                "id": 141015118,
                "url": "https://finnhub.io/api/news?id=cbf5dc445b0c76d160194163974c25631e03fe21e4e10a18d4aafdb19b3e4b54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The days ahead pack several binary or near-binary catalysts for U.S. biotech and biopharma companies—decisions that could sharply reshape valuations overnight.",
                "category": "company",
                "datetime": 1784939440,
                "headline": "FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 214,
            "discarded_article_count": 177
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日3日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 17683590,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 42640750,
              "avg_vol_20": 24018570,
              "avg_vol_30": 17683590,
              "range_pct_10": 0.8513931888544892,
              "range_pct_20": 0.8927928576571388,
              "range_pct_30": 0.8927928576571388,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 2.4113174983134082,
              "dist_to_20d_high": 0.2138005207743689,
              "down_shrink_days": 3,
              "breakout_level_20d": 176.66,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.9536290322580645
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 12.227734178126576,
              "turnoverUsdM": 4292.710869189999,
              "liquidityPoints": 0.8,
              "volatilityPoints": 0.3
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.MRNA",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 104.9238,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 24.5,
            "take_profit_price": 175.4603,
            "target_multiplier": 1.9,
            "technical_strength": 1.7,
            "take_profit_percent": 26.3
          },
          "positionPoints": 1.1,
          "stopLossPoints": 0.6,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.7533333333333334,
          "stopLossPercent": 15,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 16.9831,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 2,
      "atr_pct": 12.23
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 151.19
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "資金流入",
      "score": 8,
      "value": 0.2495
    },
    "kdj": {
      "d": 78.42,
      "j": 66.34,
      "k": 74.4,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 70.91
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 250022229,
      "recentSlope": 14938842.9,
      "previousSlope": 1032010
    },
    "rsi": 71.96,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 107.3808,
      "position": "SAR喺價下",
      "distancePct": 22.69,
      "previousTrend": "上升"
    },
    "ma50": 69.3885,
    "macd": {
      "macd": 19.068797512860996,
      "trend": "強烈看漲",
      "signal": 9.07265638761574,
      "histogram": 9.996141125245256
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 132.3097,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 11
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.22,
      "score": 6,
      "avgVolume": 25312024,
      "currentVolume": 30907271
    },
    "derived": {
      "ma20": 76.7305,
      "ma50": 69.3885,
      "prevClose": 145.13,
      "avgVolume10": 45109027,
      "avgVolume20": 25312024,
      "changePercent": -4.3,
      "avgVolumeForScore": 25312024
    },
    "ma_cross": {
      "ma20": 76.7305,
      "ma50": 69.3885,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 72.5675,
      "prevMa50": 67.6035,
      "spreadPct": 10.58,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 3.844,
      "upper": 149.617,
      "position": "上半部"
    },
    "rsi_short": 71.82,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.22
    }
  }
}

{
  "close": 138.89,
  "volume": 30907271,
  "changePercent": -4.3
}